Sustained release of VEGF through PLGA microparticles improves vasculogenesis and tissue remodeling in an acute myocardial ischemia–reperfusion model by Formiga, F.R. (Fabio R.) et al.
Sustained release of VEGF through PLGA microparticles improves vasculogenesis and 
tissue remodeling in an acute myocardial ischemia-reperfusion model 
 
Fabio R. Formiga1,*, Beatriz Pelacho2,*, Elisa Garbayo1, Gloria Abizanda2, Juan J. Gavira2, Teresa 
Simon-Yarza1, Manuel Mazo2, Esther Tamayo1, Carlos Jauquicoa3, Carlos Ortiz-de-Solorzano3, 
Felipe Prósper2,†, Maria J. Blanco-Prieto1,† 
 
1Department of Pharmacy and Pharmaceutical Technology, School of Pharmacy, University of 
Navarra, 2Hematology, Cardiology and Cell Therapy, Clínica Universidad de Navarra and 
Foundation for Applied Medical Research and 3Imaging Laboratory, Foundation for Applied 
Medical Research, University of Navarra, Pamplona, Spain. 
 
Address for correspondence: Maria J. Blanco-Prieto, Department of Pharmacy and 
Pharmaceutical Technology, School of Pharmacy, University of Navarra, Irunlarrea 1, E-31080 
Pamplona, Spain. Tel.: +34 948 425600 x 6519; fax: +34 948 425649 e-mail: mjblanco@unav.es 
and Felipe Prosper, Hematology and Cell Therapy, Clínica Universidad de Navarra, Av. Pío XII 
36, Pamplona 31008, Spain. Phone +34 948 255400 Fax +34 948 296500. E-mail: 
fprosper@unav.es 
 
*F.R. Formiga and B. Pelacho contribute equally to this manuscript. 
†Felipe Prósper and Maria J. Blanco-Prieto are equal senior authors. 
 
 1
Abstract 
The use of pro-angiogenic growth factors in ischemia models has been associated with limited 
success in the clinical setting, in part owing to the short lived effect of the injected cytokine. 
The use of a microparticle system could allow localized and sustained cytokine release and 
consequently a prolonged biological effect with induction of tissue revascularization. To 
assess the potential of VEGF165 administered as continuous release in ischemic disease, we 
compared the effect of delivery of poly(lactic-co-glycolic acid) (PLGA) microparticles (MP) 
loaded with VEGF165 with free VEGF or control empty microparticles in a rat model of 
ischemia-reperfusion. VEGF165 loaded microparticles could be detected in the myocardium of 
the infarcted animals for more than a month after transplant and provided sustained delivery 
of active protein in vitro and in vivo. One month after treatment, an increase in angiogenesis 
(small caliber caveolin-1 positive vessels) and arteriogenesis (α-SMA positive vessels) was 
observed in animals treated with VEGF microparticles (p<0.05), but not in the empty-
microparticles or free VEGF groups. Correlating with this data, a positive remodeling of the 
heart was also detected in the VEGF-microparticle group with a significantly greater LV wall 
thickness (p<0.01). In conclusion, PLGA microparticle is a feasible and promising cytokine 
delivery system for treatment of myocardial ischemia. This strategy could be scaled up and 
explored in pre-clinical and clinical studies. 
 
Key words: angiogenesis; VEGF; PLGA microparticles; Controlled Release; myocardial 
infarction. 
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1. Introduction 
Cardiovascular diseases remain the first cause of morbidity and mortality in the developed 
countries accounting for almost 30% of all deaths [1]. Despite recent evidence indicating that 
the heart is endowed with a regerative potential based on the presence of cardiac 
progenitors/stem cells, this is insufficient overall to prevent the development of cardiac failure 
after  myocardial infarct in the majority of patients [2, 3]. While heart transplant remains the 
only curative option for patients with end-stage heart failure, new approaches such as gene 
(reviewed in [4, 5]) and stem cell therapy (reviewed in [6, 7]) or even the direct 
administration of pro-angiogenic growth factors have been explored in recent years [8, 9]. In 
the case of cell therapy, the current view suggests that stem cells contribute to cardiac repair 
through a paracrine effect associated with the release of growth factors rather than by directly 
contributing to tissue regeneration [10-14].  
If the role of paracrine mechanisms is taken as a starting point, the administration of growth 
factors to promote tissue revascularization represents an attractive option that has been 
explored in animal models of limb ischemia or myocardial infarction. Pro-angiogenic 
cytokines such as VEGF (Vascular Endothelial Growth Factor), FGF (Fibroblast Growth 
Factor) or HGF (Hepatic Growth Factor) [15-18] have been administered either as natural 
recombinant human proteins or by gene transfer. However, although preclinical animal 
models and initial clinical trials suggested a beneficial effect [19-21], double-blinded clinical 
trials with large cohorts of patients failed to show efficacy [22-25]. These disappointing 
results were attributed, at least partially, to the short lived effect and high instability of the 
protein when injected as a bolus. On the other hand, gene delivery through naked plasmids or 
integrative viral vectors was associated with low efficacy, or even with risk of genome 
integration, which hinders their use in the clinical setting [23, 25, 26]. 
An alternative approach is the development of biocompatible delivery systems, allowing for 
sustained and controlled release of growth factors that could prevent some of the problems 
described, and which would at the same time facilitate stable prolonged treatment in the 
damaged tissue (reviewed in [27, 28]). To explore this possibility, we prepared poly(lactide-
co-glycolide) (PLGA) microparticles (MP) containing the angiogenic cytokine VEGF165 by 
water/oil/water (W/O/W) multiple emulsion solvent evaporation using the Total Recirculation 
One-Machine System (TROMS), a suitable technique for encapsulating proteins [29]. Next, 
we analyzed the vasculogenic effect of small-sized biodegradable and biocompatible VEGF-
loaded microparticles in a rat model of myocardial infarction induced by ischemia 
reperfusion. 
 
2. Materials and Methods 
2.1 Materials 
Recombinant human VEGF165 (rhVEGF, Sf21-derived) was purchased from R&D Systems 
(Minneapolis, MN, USA). Quantikine VEGF ELISA kit was obtained from R&D Systems 
and used according to manufacturer's instructions. PLGA with a monomer ratio (lactic 
acid/glycolic acid) of 50:50 Resomer® RG 503H (Mw: 34 kDa) was provided by Boehringer-
Ingelheim (Ingelheim, Germany). Polyethylene glycol (PEG; Mw: 400), human serum 
albumin (HSA), bovine serum albumin (BSA) and sodium azide were provided by Sigma–
Aldrich (Barcelona, Spain). Dichloromethane and acetone were obtained from Panreac 
Quimica S.A. (Barcelona, Spain). Poly(vinyl alcohol) (PVA) 88% hydrolyzed (Mw: 125,000) 
was obtained from Polysciences, Inc. (Warington, USA). Rhodamine B isothiocyanate was 
from Sigma-Aldrich (Barcelona, Spain). A human iliac artery endothelial cell line (HIAE-
101, ATCC, USA) was used in the bioactivity studies. Rabbit polyclonal anti-human VEGF-
A (clone A-20, sc-152) was supplied by Santa Cruz Biotechnology (Santa Cruz, CA, USA). 
 3
ECL™ anti-Rat IgG horseradish peroxidase-linked whole antibody was from Amersham 
Biosciences (Buckinghamshire, UK). Anti-caveolin-1α antibody was purchased from BD 
Biosciences Pharmingen (Heidelberg, Germany) and Alexa Fluor 594 goat conjugated anti 
mouse IgG was from Invitrogen (Eugene, OR, USA). Anti-alpha smooth muscle actin-Cy3 
was provided by Sigma (St. Louis, MO, USA). Rabbit anti-caveolin-1 antibody was supplied 
by Cell Signaling Technology (Danvers, MA, USA) and donkey anti-rabbit FITC was from 
Jackson ImmunoResearch (West Grove, PA, USA).  
 
2.2 Preparation of PLGA microparticles containing VEGF  
rhVEGF165-loaded microparticles were prepared by the solvent extraction/evaporation method 
using TROMS [29]. Briefly, 50 mg of PLGA were dissolved in 2 ml of a 
dichloromethane/acetone mixture. This polymer solution was injected into the inner aqueous 
phase (W1) containing 35 µg of VEGF, 5 mg of HSA and 5 μl of PEG 400 dissolved in 200 μl 
of phosphate-buffered saline (PBS). Next, the previously formed inner emulsion (W1/O) was 
recirculated through the system for 3 min under a turbulent flow regime. After this step, the 
first emulsion was injected into the outer aqueous phase (W2), composed of 30 ml of a 0.5% 
PVA solution, resulting in a multiple emulsion (W1/O/W2), which was homogenized by 
circulation through the system for 4 min. The multiple emulsion was stirred for 3 h to allow 
solvent evaporation. Microparticles were washed three times with ultrapure water by 
consecutive centrifugation at 4°C (20000 g, 10 min). Finally, the particles were resuspended 
in 1 ml of ultrapure water, frozen at -80°C, lyophilized (Genesis 12EL, Virtis) and stored at 
4°C. For fluorescence-labeled microparticle formulation, rhodamine B isothiocyanate (0.5 
mg/mL) was added to inner aqueous phase and microparticles were prepared as described.  
 
2.3 Characterization of microparticles 
2.3.1 Particle size analysis  
Particle size and particle size distribution were measured by laser diffractometry using a 
Mastersizer® (Malvern Instruments, UK). A suitable amount of freeze-dried microparticles 
was resuspended in deionized water before measurement. The average particle size was 
expressed as the volume mean diameter in micrometers. 
 
2.3.2 Determination of VEGF Encapsulation  
Encapsulation efficiency was determined via extraction with dimethyl sulfoxide (DMSO). 
Freeze-dried loaded microparticles (2 mg, n = 3) were dissolved with 250 µl of DMSO as 
previously performed [30]. The amount of VEGF entrapped in the particles was measured 
using the Quantikine VEGF ELISA kit following the manufacturer’s protocol.  
VEGF content into microparticles was also quantified using Western blot analysis. After 
VEGF extraction from microparticles with DMSO, SDS-PAGE was performed onto 12% 
polyacrylamide gels and after electrophoresis the proteins were transferred onto nitrocellulose 
membranes. After 1 h blocking with 5% nonfat dried milk in TBS plus 0.05% Tween 20, 
nitrocellulose sheets were incubated overnight at 4 °C with primary rabbit antibodies against 
VEGF-A (A-20): sc-152 (diluted 1:2000). The binding of primary antibodies was performed 
by incubating membranes with horseradish peroxidase (HRP)-conjugated anti-rabbit 
secondary antibody (diluted 1:2000). Immunoreactive bands were, after several washes, 
visualized using LumiLight Plus western blotting substrate (Roche Diagnostics, Mannheim, 
Germany). Quantitative analysis of MP-extracted VEGF bands was performed by 
densitometry using Quantity One software (Bio-Rad Laboratories Inc., Munich, Germany). 
Sample values were quantified using a standard curve.  
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2.3.3 In vitro release of VEGF from PLGA microparticles 
For determination of the cytokine release profile, 2 mg of VEGF-loaded microparticles (n = 
3) were dispersed in 100 µl of PBS, pH 7.4, containing 0.1% BSA and microbiologically 
preserved with 0.02%w/w sodium azide. Incubation took place in rotating vials maintained at 
37°C for 28 days. At defined time intervals (1 hour, 6 hours, 1, 2, 4, 7, 14, 21 and 28 days), 
sample tubes were centrifuged (25000 g, 15 min) and the supernatant was removed and frozen 
at −80°C. The removed solution was replaced with an equal volume of fresh medium. 
Supernatant protein content was determined by ELISA and western-blot assays.  
 
2.3.4 Bioactivity of released VEGF 
The bioactivity of the VEGF released from the microparticles was evaluated in vitro by 
determining the proliferative capacity of an endothelial cell line (HIAEC) after VEGF 
treatment. HIAECs were cultured in F12K media supplemented with 30 μg/mL endothelial 
cell growth supplement (ECGS), 10% fetal bovine serum, 1% heparin and 1% 
penicillin/streptomycin. In order to determine the endothelial cell proliferation capacity after 
VEGF stimulation, the HIAECs were plated into 24-well culture plates at a density of 1.25 × 
103 cells/well and microparticles were placed in an upper chamber by using transwells (0.4 
µm pore size, tissue culture treated polycarbonate membrane - Corning, USA). Cells were 
incubated for 3 or 7 days, with supernatant from non-loaded or VEGF-loaded microparticles, 
free VEGF (at 10 or 25 ng/mL), or medium alone as control. The number of viable cells in 
each experimental group was determined by ATP quantitation, which signals the presence of 
metabolically active cells by using the CellTiter-Glo® Luminescent Cell Viability Assay 
(Promega, USA). Moreover, in order to confirm the VEGF bioactivity, the capability of the 
released VEGF to activate its receptor (KDR) in the cultured HIAECs was evaluated by 
measuring KDR-tyrosine phosphorylation using an ELISA assay (DuoSet® IC for human 
phospho-VEGF R2/KDR, R&D Systems, Minneapolis, MN, USA). 
 
2.4 In vivo experiments 
2.4.1 Myocardial Infarction Model  
The investigation conforms to the Guide for the Care and Use of Laboratory Animals 
published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996). 
All animal procedures were approved by the University of Navarra Institutional Committee 
on Care and Use of Laboratory Animals as well as the European Community Council 
Directive Ref. 86/609/EEC. A total of 30 female Sprague-Dawley rats (250-300 g) were 
obtained from Harlan-IBERICA (Barcelona, Spain). Animal experiments were carried out 
using a rat model of cardiac acute-reperfusion ischemia. Rats were initially anesthetized with 
4% isoflurane in an induction chamber. Prior to surgery, animals received analgesic drug 
ketoprofen 5 mg/Kg subcutaneously, fentanyl 0.15 mg/kg and heparin 0.1 mg/kg both 
administered by intraperitoneal route. The rats were then intubated and ventilated at 90 
cycles/min (1.5-2% isoflurane was maintained for continuous anesthesia). A left thoracotomy 
through the fourth intercostal space was performed, and the left anterior descending (LAD) 
coronary artery was occluded 2-3 mm distal from its origin for 1 hour and then re-opened. 
The chest was then closed in layers and rats allowed to recover.  Those rats with an ejection 
fraction bellow 55% (as determined by echocardiography) 2 days after myocardial infarction 
were included in the study. 
 
2.4.2 Intramyocardial administration of microparticles 
Four days after LAD coronary artery occlusion, 2 mg of VEGF-loaded microparticles or free 
VEGF (100 ng), or non-loaded microparticles (NL-MP) were injected with a 29-gauge needle 
into 4 regions in the border zone surrounding the infarct. Prior to injection, freeze-dried 
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microparticles were dispersed in a sterile buffered solution consisting of 0.1% (w/v) 
carboxymethylcellulose, 0.8% (w/v) polysorbate 80 and 0.8% (w/v) mannitol in PBS, pH 7.4. 
All groups received the same volume of buffered solution (100 µl) and 6 animals were 
included in each group. The chest was closed and rats were allowed to recover.  
 
2.4.3 PLGA-microparticles visualization in the myocardium 
In order to evaluate the persistence of PLGA microparticles in the heart tissue, a group of 
infarcted animals was sacrificed 8 and 30 days after fluorescent-labelled microparticle 
administration (drug-free). Rhodamine B was used as a fluorescent marker to localize the 
injected microparticles by fluorescent microscopy in the heart tissue.  
 
2.5 Morphometric Study  
Four weeks post-injection, animals were sacrificed and their hearts were collected for 
subsequent morphometric and histological analysis. After being harvested, the hearts were 
weighed and perfused-fixed in 4% paraformaldehyde at 4°C, and sliced in three 4-mm-thick 
segments from apex to base. The hearts were dehydrated in ethanol 70% at 4°C and 
embedded in paraffin. Sections (5 µm) were cut from each segment and stained with Sirius 
Red as previously described [31] to evaluate infarct wall thickness. These morphometric 
parameters were measured in images made with a 5× objective of Sirius Red-stained sections 
viewed with a Zeiss Axio Imager M1 microscope (Carl Zeiss AG, Oberkochen, Germany) 
and captured using an Axio Cam ICc3 video camera and Axiovision software (4.6.3.0 
version). Fibrosis was measured in high power photographs within the infarct border as the 
percentage of collagen area (red) vs. total tissue area, using AnalySIS® software (Soft 
Imaging System GmbH, Münster, Germany). 
 
2.6 Histological Study 
For the analysis of capillary density (capillaries/mm2), 9 sections per heart were stained with 
an anti-caveolin-1α antibody (diluted 1:50) and 2 peri-infarct and 2 intra-infarct images per 
section were analyzed. Secondary antibody was Alexa Fluor 594 goat conjugated anti mouse 
IgG (diluted 1:100). The arteriolar density and arteriolar area were quantified in the same way 
after staining with anti-alpha smooth muscle actin-Cy3 (α-SMA, diluted 1:500) in the 
following sections. For vessel counting, images were acquired using the Axio Cam MR3 
video camera at 20× connected to the Zeiss Axio Imager M1 microscope equipped with 
epifluorescence optics. Digital images were analyzed using MatLab® software platform 
(Mathworks Inc., Natick, MA, USA). Also, double immunostaining with anti-alpha smooth 
muscle actin-Cy3 and rabbit anti-caveolin-1 (diluted 1:125) was performed. Secondary 
antibody was donkey anti-rabbit FITC (diluted 1:200) and nucleus were stained with TOPRO-
3 (diluted 1:50 in PBS-glycerol). For confocal microscopy, a LSM 510 META (Carl Zeiss, 
Minneapolis, USA) microscope was utilized. 
 
2.7 Statistical analysis 
Results are expressed as mean ± SEM. Statistics were calculated with SPSS computer 
software for Windows (version 15.0, SPSS Inc, Chicago, Ill). Non-parametric statistical 
analyses were used when values were not normally distributed. The differences among the 
groups were first evaluated using the Kruskall–Wallis test, followed by Mann–Whitney U-test 
comparing individual groups where necessary. The differences among the groups were 
assessed by ANOVA with a Tukey post hoc correction when the measured values were 
normally distributed. Shapiro-Wilk test was used to justify the use of a parametric test. A 
value of p<0.05 was considered statistically significant. 
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3. Results 
3.1 Characterization of PLGA-microparticles, VEGF165 release and bioactivity  
VEGF-loaded microparticles (VEGF-MP) were prepared with a diameter of 5.1±1.3 µm 
(Fig.1A). The total amount of loaded VEGF was 0.58 µg per mg of polymer, which 
corresponds to an encapsulation efficiency of 83.8±6.6% determined by ELISA and 
confirmed by Western Blot analysis (not shown). The yield of the microencapsulation process 
was over 80%.  
The in vitro release kinetics was performed in PBS (pH 7.4) at 37 ºC for 28 days. VEGF 
released within the first 6 hours (burst effect) was 10±1%, followed by a phase of sustained 
release of the cytokine with almost 75% of VEGF being released within 28 days (Fig.1B).  
 
 
 
 
Figure 1: Microparticle characterization and Release Profile. A. Representative particle size distribution for 
PLGA microparticles prepared by TROMS employed in the in vivo studies. B. In vitro release of VEGF from 
PLGA microparticles. 
 
The bioactivity of the encapsulated VEGF165 released from the microparticles was examined 
by determining its capacity to induce proliferation of endothelial cells (Human Iliac Artery 
Endothelial Cells HIAEC). VEGF-MP (10 or 25 ng/mL) induced a 2-3 fold increase in 
proliferation of HIAEC in comparison with control (no cytokine) or non-loaded MP (NL-MP) 
after 3 and 7 days in culture (p<0.01). This increase was similar to that observed when 
HIAEC cells were cultured with daily addition of free VEGF at doses of 10 or 25ng/mL 
(Fig.2A). In addition, bioactivity of the VEGF-MP was further determined by quantifying the 
tyrosine phosphorylation of the VEGF receptor KDR. Similar levels of stimulation in the 
HIAEC cells treated either with the free-VEGF or the VEGF-MP was detected, confirming 
the bioactivity of the released protein (Fig.2B).  
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Figure 2: Bioactivity of VEGF-MP.  A. Proliferation of HIAEC cells was induced by free VEGF at 10ng/mL 
(VEGF-10) or 25ng/mL (VEGF-25) or VEGF-MP at the same concentration and compared to culture medium 
alone (control) for 3 and 7 days. Non-loaded microparticles (NL-MP) did not induce cell proliferation. 
Representative pictures of HIAECs density 7 days after treatment are shown. B. KDR activation in HIAECs 
induced by VEGF stimulation (free or encapsulated at 10ng/mL) and NL-MP (y axis represents fold increase 
versus non treated group). *P<0.05 and **P<0.01. 
 
3.2 Microparticle visualization in the heart tissue 
In order to confirm the capacity of the microparticles to remain in the myocardium for a 
prolonged period of time -a requirement for sustained cytokine treatment-, the fate of the 
particles after in vivo administration was assessed. Rhodamine-labeled microparticles were 
injected into the peri-infarcted area of the myocardium and animals were sacrificed at 1 and 4 
weeks. The fluorescent-labeled microparticles were visible by fluorescence microscopy for up 
to a month post-implantation (Fig.3A-E). Furthermore, partial degradation of the particles was 
observed after one month, indicating the biodegradable nature of the co-polymer (Fig.3D,E). 
 
 
 8
 
Figure 3: (A) PLGA-microparticles visualization in the heart tissue. A. Microscopy fluorescence 
visualization of a heart cross-section after fluorescent-labelled microparticle administration. B-E. Rhodamine-
labeled-microparticles distribution 1 week (B,C) and 1 month (D,E) after injection. Nuclear staining was 
performed with DAPI (blue). Scale bars: 500 µm (A), 100 µm (B,D) and 20 µm (C,E).  
 
3.3 Vasculogenic and tissue remodeling effect of treatment with VEGF-MP  
Administration of VEGF-MP in infarcted rats was associated with a statistically significant 
increase in the number of capillaries in the infarct and peri-infarct areas of the injured hearts 
in comparison with the control group (non-loaded microparticles: NL-MP) or with animals 
treated with free VEGF (NL-MP: 579.5±33.8; VEGF-MP: 704.9±31.75, P<0.05; Free-VEGF: 
571.6±37.3, P=NS, capillaries/mm2) (Fig.4A). Treatment with VEGF-MP not only induced a 
significant increase in small caliber vessels, but also in the number of arterioles (α-SMA 
coated vessels). This effect was only detected in the hearts treated with the VEGF-MP and not 
in the hearts injected with the free cytokine, which showed a similar vessel density to animals 
treated with non-loaded MP (NL-MP: 70±6.7; VEGF-MP: 95±8.9, P<0.05; Free-VEGF: 
55±4.5, P=NS, arterioles/mm2) (Fig.4B). In line with these results, the area occupied by α-
SMA-positive-vessels (µm2) was significantly increased in animals treated with VEGF-MP 
(NL-MP: 3347±183; VEGF-MP: 6590±764, P<0.001; Free-VEGF: 2170±328, P=NS). No 
hemangioma formation or leaking vessels were detected in the VEGF-MP group in the 
analysis of hematoxylin-eosin stained sections, confocal 3D analysis of caveolin-1+ stained 
vessels -where non-leaking vessels were detected- (Fig.5A,B), and confocal analysis of 
caveolin-1+/α-SMA double-stained vessels, which showed a tightly association between the 
endothelial and mural cell layers (Fig.5C-E). 
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Figure 4: In vivo effects of VEGF-MP. Capillary (A) and arteriole (B) densities were determined by 
quantification of the small caliber (<15µm) caveolin-1-positive capillaries/mm2 and α-SMA-positive 
vessels/mm2 in the infarcted and peri-infarcted areas, 1 month after administration of non-loaded MP (NL-MP) 
(control group), VEGF-MP or free-VEGF. Representative images for caveolin-1α and α-SMA 
immunofluorescence stainings are shown. A significant increase in capillary and arteriole densities was 
determined in the hearts injected with VEGF-MP in comparison with the control group (*P<0.05). No 
significant increase was detected in the free-VEGF group. Data are presented as mean ± SEM. Scale bars: 50 
µm.  
 
 
 
Figure 5: Vessel structure. A,B. Tri-dimensional views of caveolin-1-positive vessels in the VEGF-MP group. 
Note that the vessels display a regular endothelial structure. C-E. Representative pictures of αSMA-Cy3 (red) 
and Caveolin-1 (green) double immunostained vessels in VEGF-MP-treated heart sections, showing tightly 
contact between the smooth muscle and the endothelial cell layers. Nuclear staining was performed with 
TOPRO-3 (blue). Scale bars: 100 µm (A), 400 µm (B), 20 µm (C-E), 5 µm (E, insert). 
 
The increased revascularization of the tissue translated into a beneficial effect in the 
remodeling processes, with a significantly greater thickness of the left ventricle wall in the 
VEGF-MP treated animals in comparison with the control group (NL-MP: 1.07±0.02 mm; 
VEGF-MP: 1.30±0.05 mm (P<0.01); Free-VEGF: 1.07±0.10 mm (P=NS)) (Fig.6), suggesting 
a potential benefit related to the administration of VEGF through a sustained release system in 
comparison with injection of the free cytokine. 
 
 
 
Figure 6: Heart remodeling. Representative Sirius red stained heart sections show greater thickness of the LV 
wall of the VEGF-MP group in comparison with the NL-MP (control group) (**P<0.01). No significant increase 
was detected in the free-VEGF treated group. Scale bars: 1 mm. 
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4. Discussion  
In patients with myocardial ischemia, therapeutic angiogenesis by direct delivery of the 
VEGF protein or using gene therapy approaches has not yielded the expected results in 
clinical practice [32]. Some important limitations, such as the short half-life of the protein, as 
well as the relatively short effect of naked plasmids or adenovirus transfection, seemed to be 
responsible, at least partially, for the lack of success. Alternative strategies that allow a local, 
sustained delivery of VEGF or other angiogenic cytokines are worth exploring in order to 
induce a therapeutic effect. The development of PLGA microparticles loaded with VEGF 
shown in our study fulfills many of the requirements for a potentially successful therapy like 
the possibility of being readily administered and their permanence in the myocardium for at 
least 30 days, being capable of a sustained delivery of active cytokine during that period of 
time.  
Therefore, treatment with VEGF-MP was associated with the expected biological effect: 
increased angiogenesis and arteriogenesis in an acute ischemia-reperfusion model. Other 
delivery systems based on the use of hydrogels, liposomes, nanoparticle-fibrin complex, 
collagen-bound proteins or polymer scaffolds with VEGF or other cytokines have also been 
explored, showing an angiogenic effect after sustained cytokine treatment [33-37]. However, 
in general the control of release rate of growth factors from hydrogels is difficult and a strong 
initial burst release is generally observed which has been associated with severe side effects, 
such as hypotension [33]. Interestingly, targeted delivery has recently been achieved by anti-
P-selectin-conjugated liposomes, which induced an increase in tissue vascularization and an 
improvement in the cardiac function [34]. Unfortunately, the need for very early delivery (a 
down-regulation of the receptor in the infarcted area occurs 24h after the ischemia) [38] 
represents a challenge for its therapeutic use in patients.  
VEGF is known to be a potent key regulator of blood vessel formation during both 
angiogenesis and vasculogenesis (reviewed in [39]). Endothelial cells are activated by VEGF, 
which results in increased vessel permeability, cell migration and proliferation. Indeed, local 
high levels of VEGF may result in deleterious effects including the formation of irregularly 
shaped sac-like vessels associated with massive and highly disruptive edema [40] or even 
formation of endothelial cell-derived intramural vascular tumors [41]. The sustained 
controlled release provided by the PLGA particles seems to circumvent these potential 
problems, as none were found in our study. The positive effects of VEGF-MP on the 
induction of angiogenesis were not observed in animals treated with NL-MP or even with 
free-VEGF, demonstrating the greater effect of long-term-release VEGF. As it has been 
previously demonstrated, a short VEGF stimulus, if it is not sustained, is associated with the 
regression of the newly formed vessels when discontinued [40]. 
Treatment with VEGF-MP induced not only an increase in capillaries, but also in vessels of 
greater caliber, suggesting that prolonged release of VEGF indirectly promotes arteriogenesis 
by stabilizing the vessels through pericyte and/or smooth muscle recruitment and proliferation 
(reviewed in [42]). It has been suggested that VEGF can induce the proliferation of local 
pericytes by stimulating endothelial cells to express PDGF (platelet-derived growth factor) 
[43], which exerts a chemotactic and differentiation effect in pericytes. Furthermore, the 
presence of the VEGF receptor in pericytes has also been shown [44], implying that VEGF 
can act directly on the pericytes by stimulating migration and proliferation. Interestingly, 
sustained VEGF-MP treatment induced an increase in the number of arteriolar vessels, 
favoring tissue irrigation [45] and consequently, rescuing the tissue areas at risk. It is possible 
that preexisting capillaries could undergo enlargement and/or fusion and recruit a smooth 
muscle cell coating as a consequence of the sustained VEGF-stimulation [45-47]. On the 
other hand, the presence of VEGF receptors in cardiomyocytes and their association with a 
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protective effect has been reported [48], which could be responsible, together with the 
revascularization effect, for the rescue of the cardiac tissue, which translated in a positive 
remodeling of the heart. 
Timing and combination of cytokine administration is an important issue. VEGF-MP were 
administered alone and shortly after the ischemic event. From the results of this study and 
others where cytokine was given immediately after myocardial infarction, it seems that very 
early injection of the cytokine might favor its therapeutic benefit by rescuing hibernating 
cardiac tissue. On the other hand, the combination of other cytokines that contribute to vessel 
maturation such as PDGF, TGFβ, FGF, or angiopoietins or even combination of cytokines 
and (stem) cells could induce a stronger beneficial effect [49-51]. Thus, for example, it has 
been shown, that subcutaneous implantation of a polymer scaffold that released VEGF165 and 
PDGF-BB induced rapid formation of a mature vascular network [52]. 
 
Conclusions 
In summary, we have demonstrated that a single cytokine, VEGF, could exert not only an 
angiogenic but also an arteriogenic effect when delivered in vivo in a sustained manner, which 
translates into positive remodeling of the heart. Moreover, the use of microparticles allows a 
dose-controlled release of the protein that can be easily and safely translated to patients.  
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